Impact of baseline PINP on the BMD increase with romosozumab, teriparatide, and denosumab in treatment-naïve primary osteoporosis: A retrospective cohort study

Etani, Yuki; Noguchi, Takaaki; Yukishima, Toshitaka; Kobayakawa, Tomonori; Kashii, Masafumi; Okamura, Gensuke; Goshima, Atsushi; Hirao, Makoto; Miura, Taihei; Kurihara, Takuya; Fukuda, Yuji; Sugimoto, Atsushi; Okada, Seiji; Nakata, Ken; Ebina, Kosuke

doi:https://doi.org/10.1016/j.bone.2025.117627

Impact of baseline PINP on the BMD increase with romosozumab, teriparatide, and denosumab in treatment-naïve primary osteoporosis: A retrospective cohort study

Etani, Yuki; Noguchi, Takaaki; Yukishima, Toshitaka et al.

Bone, 2025, 201, 117627

アクセス数:2件（2025-10-31 05:56 集計）

固定URL: https://hdl.handle.net/11094/102874

閲覧可能ファイル

ファイル	フォーマット	利用条件	サイズ	閲覧回数	利用開始日	説明	information
Bone_201	pdf	なし	1.68 MB	5	2025.10.27

Creative Commons : 表示 - 非営利 - 改変禁止

論文情報

ファイル出力 EndNote Basic出力 Mendeley出力

タイトル	Impact of baseline PINP on the BMD increase with romosozumab, teriparatide, and denosumab in treatment-naïve primary osteoporosis: A retrospective cohort study
著者	NRID 1000060898930 1000060898930 ORCID 0000-0001-5741-5969 0000-0001-5741-5969 researchmap permalink Yetani0302 Yetani0302 Scopus Author ID 57209857251 57209857251 著者名 Etani, Yuki
	NRID 1000050812294 1000050812294 ORCID 0000-0001-9938-6780 0000-0001-9938-6780 researchmap permalink takaakinoguchi takaakinoguchi Scopus Author ID 56797347500 56797347500 著者名 Noguchi, Takaaki
	著者名 Yukishima, Toshitaka
	著者名 Kobayakawa, Tomonori
	NRID 1000000576910 1000000576910 著者名 Kashii, Masafumi
	著者名 Okamura, Gensuke
	著者名 Goshima, Atsushi
	NRID 1000010527708 1000010527708 著者名 Hirao, Makoto
	著者名 Miura, Taihei
	著者名 Kurihara, Takuya
	著者名 Fukuda, Yuji
	著者名 Sugimoto, Atsushi
	NRID 1000030448435 1000030448435 ORCID 0000-0002-5107-8209 0000-0002-5107-8209 researchmap permalink okadaseiji okadaseiji Scopus Author ID 35079139100 35079139100 著者名 Okada, Seiji
	NRID 1000000283747 1000000283747 researchmap permalink ken-nakata ken-nakata Scopus Author ID 7402151308 7402151308 著者名 Nakata, Ken
	NRID 1000070612076 1000070612076 ORCID 0000-0002-2426-1024 0000-0002-2426-1024 researchmap permalink k-ebina k-ebina Scopus Author ID 8415453300 8415453300 著者名 Ebina, Kosuke
キーワード等	Bone mineral density
	Bone turnover marker
	Denosumab
	N-terminal type I procollagen propeptide
	Romosozumab
	Teriparatide
内容	Etani Y., Noguchi T., Yukishima T., et al. Impact of baseline PINP on the BMD increase with romosozumab, teriparatide, and denosumab in treatment-naïve primary osteoporosis: A retrospective cohort study. Bone 201, 117627 (2025); https://doi.org/10.1016/j.bone.2025.117627.
抄録	Purpose: To investigate the impact of baseline total N-terminal propeptide of procollagen (PINP) levels on increases in bone mineral density (BMD) after treatment with romosozumab (ROMO), teriparatide (TPTD), and denosumab (DMAb) in patients with treatment naïve primary osteoporosis. Methods: This multicenter, retrospective cohort study included 462 treatment-naïve patients (88.7 % female; mean age, 75.5 years; baseline BMD T-scores: lumbar spine [LS], −3.0; total hip [TH], −2.7) who initiated treatment with ROMO (n = 310), TPTD (n = 70), or DMAb (n = 82). Patients were stratified by baseline total PINP levels into low (≤ 70.1 μg/L) and high (> 70.1 μg/L) groups. After adjusting for baseline characteristics using inverse probability of treatment weighting, changes in BMD were evaluated at 12 months. Results: In the low PINP group, increases in LS BMD were similar between ROMO and TPTD; in the high PINP group, ROMO led to greater increases in LS BMD than TPTD. ROMO resulted in greater increases in TH BMD than TPTD, regardless of PINP level. Compared with DMAb, ROMO resulted in greater increases in LS BMD and TH BMD in the low PINP group, whereas no significant differences were observed in the high PINP group. Conclusion: ROMO demonstrated robust increases in both LS and TH BMD across all PINP levels. TPTD led to increases in LS BMD comparable to those with ROMO in the low PINP group. DMAb led to increases in both LS and TH BMD comparable to those with ROMO in the high PINP group.
出版者	Elsevier Inc.
収録物名	Bone
巻(号)	201
ページ	117627
刊行年月	2025-12-01
言語	英語
ハンドルURL	https://hdl.handle.net/11094/102874
PISSN	87563282
関連情報 (isIdenticalTo)	DOI (出版社版) https://doi.org/10.1016/j.bone.2025.117627
アクセス権	open access
権利情報	This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
出版タイプ	Version of Record
カテゴリ	学術雑誌論文 Journal Article

資源タイプ	学術雑誌論文
ローカル資源タイプ	学術雑誌論文
DCMI資源タイプ	text
DCTERMS.bibliographicCitation	Bone. 2025, 201, p. 117627
DC.title	Impact of baseline PINP on the BMD increase with romosozumab, teriparatide, and denosumab in treatment-naïve primary osteoporosis: A retrospective cohort study
DC.creator	Etani, Yuki
	Noguchi, Takaaki
	Yukishima, Toshitaka
	Kobayakawa, Tomonori
	Kashii, Masafumi
	Okamura, Gensuke
	Goshima, Atsushi
	Hirao, Makoto
	Miura, Taihei
	Kurihara, Takuya
	Fukuda, Yuji
	Sugimoto, Atsushi
	Okada, Seiji
	Nakata, Ken
	Ebina, Kosuke
DC.publisher	Elsevier Inc.
DC.language' scheme='DCTERMS.RFC1766	英語
DC.type' scheme='DCTERMS.DCMIType	text
DCTERMS.issued' scheme='DCTERMS.W3CDTF	2025-12-01
DC.identifier	https://doi.org/10.1016/j.bone.2025.117627
DC.subject	Bone mineral density
	Bone turnover marker
	Denosumab
	N-terminal type I procollagen propeptide
	Romosozumab
	Teriparatide
DC.description	Etani Y., Noguchi T., Yukishima T., et al. Impact of baseline PINP on the BMD increase with romosozumab, teriparatide, and denosumab in treatment-naïve primary osteoporosis: A retrospective cohort study. Bone 201, 117627 (2025); https://doi.org/10.1016/j.bone.2025.117627.
DCTERMS.abstract	Purpose: To investigate the impact of baseline total N-terminal propeptide of procollagen (PINP) levels on increases in bone mineral density (BMD) after treatment with romosozumab (ROMO), teriparatide (TPTD), and denosumab (DMAb) in patients with treatment naïve primary osteoporosis. Methods: This multicenter, retrospective cohort study included 462 treatment-naïve patients (88.7 % female; mean age, 75.5 years; baseline BMD T-scores: lumbar spine [LS], −3.0; total hip [TH], −2.7) who initiated treatment with ROMO (n = 310), TPTD (n = 70), or DMAb (n = 82). Patients were stratified by baseline total PINP levels into low (≤ 70.1 μg/L) and high (> 70.1 μg/L) groups. After adjusting for baseline characteristics using inverse probability of treatment weighting, changes in BMD were evaluated at 12 months. Results: In the low PINP group, increases in LS BMD were similar between ROMO and TPTD; in the high PINP group, ROMO led to greater increases in LS BMD than TPTD. ROMO resulted in greater increases in TH BMD than TPTD, regardless of PINP level. Compared with DMAb, ROMO resulted in greater increases in LS BMD and TH BMD in the low PINP group, whereas no significant differences were observed in the high PINP group. Conclusion: ROMO demonstrated robust increases in both LS and TH BMD across all PINP levels. TPTD led to increases in LS BMD comparable to those with ROMO in the low PINP group. DMAb led to increases in both LS and TH BMD comparable to those with ROMO in the high PINP group.
DC.rights	This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
DC.format	102874
citation_title	Impact of baseline PINP on the BMD increase with romosozumab, teriparatide, and denosumab in treatment-naïve primary osteoporosis: A retrospective cohort study
citation_author	Etani, Yuki
	Noguchi, Takaaki
	Yukishima, Toshitaka
	Kobayakawa, Tomonori
	Kashii, Masafumi
	Okamura, Gensuke
	Goshima, Atsushi
	Hirao, Makoto
	Miura, Taihei
	Kurihara, Takuya
	Fukuda, Yuji
	Sugimoto, Atsushi
	Okada, Seiji
	Nakata, Ken
	Ebina, Kosuke
citation_publisher	Elsevier Inc.
citation_language	英語
citation_date	2025-12-01
citation_journal_title	Bone
citation_volume	201
citation_firstpage	117627
citation_doi	https://doi.org/10.1016/j.bone.2025.117627
citation_public_url	https://hdl.handle.net/11094/102874

Impact of baseline PINP on the BMD increase with romosozumab, teriparatide, and denosumab in treatment-naïve primary osteoporosis: A retrospective cohort study

閲覧可能ファイル

論文情報

論文詳細を表示